|4Feb 10, 4:59 PM ET

Akinsanya Karen 4

4 · Schrodinger, Inc. · Filed Feb 10, 2023

Insider Transaction Report

Form 4
Period: 2023-02-09
Akinsanya Karen
President of R&D, Therapeutics
Transactions
  • Award

    Stock Option (right to buy)

    2023-02-09+63,27063,270 total
    Exercise: $23.29Exp: 2033-02-09Common Stock (63,270 underlying)
Footnotes (1)
  • [F1]The option was granted on February 9, 2023. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 9, 2024 and the remainder are scheduled to vest in equal monthly installments through February 9, 2027.

Documents

1 file
  • 4
    wf-form4_167606638377104.xmlPrimary

    FORM 4